MDACC Study No:2003-0578 ( NCT No: NCT01159028)
Title:A Phase I Clinical Trial to Study the Safety, Pharmacokinetics, and Efficacy of BP-100-1.01 (L-Grb-2 Antisense Oligonucleotide) in Patients with Refractory or Relapsed Acute Myeloid Leukemia, Philadelphia Chromosome Positive Chronic Myelogenous Leukemia, or Acute Lymphoblastic Leukemia, and Myelodysplastic Syndrome
Principal Investigator:Jorge Cortes
Treatment Agent:L-Grb-2 Antisense Oligonucleotide
Study Status:Open
Study Description:The goal of this clinical research study is to find the highest safe dose of a
liposomal Growth Factor Receptor Bound Protein-2 antisense oligodeoxynucleotide
(L-Grb2 AS) that can be given as treatment for patients with Philadelphia
Chromosome positive CML and other disease conditions described earlier. The
trade name of this drug is BP-100-1.01. The response of the leukemia to this
treatment will also be studied. In addition, the time needed for the body to
process this drug will be evaluated.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase I
Treatment Agents:L-Grb-2 Antisense Oligonucleotide
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:No hospitalizations are expected.
Supported By:N/A
Return Visit:Patients must return to clinic twice weekly.
Home Care:All treatment will be administered at M.D. Anderson Cancer Center in the
Clinical and Translational Research Center.

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jorge Cortes
For Clinical Trial Enrollment:713-794-5783
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults